Key result
This review highlights the unique pharmacokinetic and electrophysiologic challenges of administering antiarrhythmic drug therapy in neonates, with an emphasis on newer available agents.
This review highlights the unique pharmacokinetic and electrophysiologic considerations for antiarrhythmic drug therapy in neonates.
Answers are grounded in this paper and cite their sources.
May warrant cautious dosing of antiarrhythmics in neonates; extends literature on newer agents but leaves open prospective validation.
The neonate presents a challenge for the practitioner considering antiarrhythmic therapy: pharmacokinetics are different than in older children or adults; and the arrhythmia substrate may also differ, with respect to issues of ion channel and autonomic nervous system development. This paper reviews the need for antiarrhythmic drug therapy in the neonate, developmental aspects of pharmacokinetics, autonomic regulation and cellular electrophysiology and the antiarrhythmics available today with an emphasis on newer drug therapy.
No takes yet. Share an insight, caveat, or question.
Anne M. Dubin (2000) conducted a review in Arrhythmia. Antiarrhythmic drug therapy was evaluated. This review highlights the unique pharmacokinetic and electrophysiologic challenges of administering antiarrhythmic drug therapy in neonates, with an emphasis on newer available agents.
Synapse has enriched 10 related papers. Consider them for comparative context: